Skip to main content
AAN.com

Abstract

We modified the World Federation of Neurology (WFN) diagnostic criteria for ALS to facilitate early diagnosis and used these criteria for enrollment of ALS patients in a clinical trial. The criteria developed required lower motor neuron (LMN) involvement in at least two limbs and upper motor neuron involvement in at least one region (bulbar, cervical, or lumbosacral). The EMG finding of fibrillation potentials was required for evidence of LMN involvement. Electrodiagnostic studies, neuroimaging, and laboratory studies were also used to exclude disorders that might mimic ALS. Using these criteria, the diagnosis of ALS was made at a mean time of 9.7 months from onset of symptoms, which compares favorably with the 12-month period cited in the literature. Using clinical assessment at completion of the trial, the diagnosis of ALS was believed to be accurate in those patients entered in the trial. However, pathologic confirmation of the diagnosis of ALS was not obtained. Based on our preliminary experience, we propose that these ALS diagnostic criteria will facilitate early diagnosis of ALS. Future studies should prospectively compare these criteria with the WFN criteria currently in use.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(Suppl):96-107.
2.
Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-637.
3.
Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 1996;347:1425-1431.
4.
Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymmidine (AZT) in the treatment of patients with aids and aids-related complex. a double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-191.
5.
Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
6.
Miller RG, Petajan J, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol 1996;39:256-260.
7.
Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. The Practitioner 1964;192:540-542.
8.
Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: electrodiagnostic features. Muscle Nerve 1994;17:198-205.
9.
Caroscio JT, Mulvihill MN, Sterling R, et al. Amyotrophic lateral sclerosis-its natural history. Neurol Clin 1987;5:1-9.
10.
Mulder DW. Motor neuron disease. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, eds. Peripheral neuropathy, ed 2, Vol. 2. Philadelphia, PA: WB Saunders, 1984;1525-1536.
11.
ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46:1244-1249.
12.
Chaudhuri KR, Crump SJ, Al-Sarraj S, et al. The validation of El Escorial criteria for the diagnosis of amyotrophic lateral sclerosis: a clinico-pathological study. J Neurol Sci 1995;129(Suppl): 11-12.
13.
Lambert EH. Electromyography in amyotrophic lateral sclerosis. In: Norris FJ, Kurland LT, eds. Motor neuron disease. New York: Grune and Stratton, 1969;135-153.
14.
Daube J. Electrophysiologic studies in the diagnosis and prognosis of motor neuron diseases. Neurol Clin 1985;3:473-491.
15.
Armon C. Motor neuron disease. In: Gorelick PB, Alter M, eds. Handbook of neuroepidemiology. New York: Marcel Dekker, 1994;407-454.

Information & Authors

Information

Published In

Neurology®
Volume 50Number 3March 1998
Pages: 768-772
PubMed: 9521272

Publication History

Published online: March 1, 1998
Published in print: March 1998

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

The rhCNTF ALS Study Group*

Notes

Address correspondence and reprint requests to Dr. Mark A. Ross, Department of Neurology, University of Iowa Hospitals, 200 Hawkins Drive, Iowa City, IA 52242.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Evolution of the Amyotrophic Lateral Sclerosis Diagnostic Criteria Towards the Gold Coast Criteria, Journal of Electrodiagnosis and Neuromuscular Diseases, 25, 3, (100-104), (2023).https://doi.org/10.18214/jend.2023.00171
    Crossref
  2. Considerations on the concept, definition, and diagnosis of amyotrophic lateral sclerosis, Neural Regeneration Research, 16, 9, (1723), (2021).https://doi.org/10.4103/1673-5374.306065
    Crossref
  3. Sleep-Disordered Breathing in Patients with Motor Neurone Disease: One Size Does Not Fit all, Neurodegenerative Diseases, 20, 4, (131-138), (2021).https://doi.org/10.1159/000513887
    Crossref
  4. Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 22, 5-6, (388-394), (2021).https://doi.org/10.1080/21678421.2021.1885448
    Crossref
  5. Challenges in diagnosis of motor neuron disease: A case series of ALS mimic syndromes, Revue Neurologique, 177, 6, (699-706), (2021).https://doi.org/10.1016/j.neurol.2020.08.010
    Crossref
  6. Correlational Analysis of ALS Progression and Serum NfL Measured by Simoa Assay in Chinese Patients, Frontiers in Neurology, 11, (2020).https://doi.org/10.3389/fneur.2020.579094
    Crossref
  7. Amyotrophic Lateral Sclerosis, Handbook of Research on Critical Examinations of Neurodegenerative Disorders, (322-346), (2019).https://doi.org/10.4018/978-1-5225-5282-6.ch015
    Crossref
  8. The revised El Escorial criteria “clinically probable laboratory supported ALS”—once a promising now a superfluous category?, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 21, 1-2, (24-28), (2019).https://doi.org/10.1080/21678421.2019.1666875
    Crossref
  9. Diagnostic criteria for amyotrophic lateral sclerosis: A multicentre study of inter-rater variation and sensitivity, Clinical Neurophysiology, 130, 2, (307-314), (2019).https://doi.org/10.1016/j.clinph.2018.11.021
    Crossref
  10. A review of electrophysiological studies of lower motor neuron involvement in amyotrophic lateral sclerosis, Neurological Sciences, 40, 6, (1125-1136), (2019).https://doi.org/10.1007/s10072-019-03832-4
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share